Evaluation of Intraprostatic Fiducial Markers For External Beam Radiation Therapy

Primary Objective:

• To collect data on the distribution among patients of the difference in location of the prostate relative to the isocenter as determined by two methods:
• The minimally invasive, fiducial-based localization system (Acculoc System) for prostate cancer external beam radiotherapy
• Computed tomography (CT) images using a CT-on-rails system

Secondary Objectives:

• To describe how the difference of the position of the prostate's center of mass (COM) as determined by CT and the mean position of the implanted fiducials (MPIF) changes over time for a group of patients
• To collect data and compare the changes in x, y, z treatment couch shifts as determined by the fiducial system and by transabdominal ultrasound of the prostate

The prostate may change position on a day-to-day basis due to differences in positioning, muscle tone, rectal filling, and bladder filling. Soft tissue like the prostate is not usually visible with normal x-rays, but certain metals like gold are visible. Many institutions are using an FDA-approved system (fiducial system), the one being used in this study, which involves implanting small gold markers to locate the prostate on a daily basis. This system allows the prostate to be located before treatment, which may improve radiation delivery to the prostate and decrease radiation exposure to normal tissue such as the rectum and bladder. The ability of this system to provide information on the location of the prostate before treatment should allow for more precise and accurate radiation treatment of prostate cancer.

The small implanted gold markers are 3 mm long and 1 mm wide (about the size of a grain of rice). If you agree to take part in this study, 3 markers will be permanently implanted into your prostate using a needle similar to the biopsy needle used to diagnose your cancer.

Treatment for prostate cancer during this research study will not be different from the M. D. Anderson standard of care. You will have intensity-modulated radiation therapy (IMRT) treatment for the prostate cancer performed using the CT-Linac treatment machine (ExaCT, Varian Medical Systems, Palo Alto, CA). This machine will have the same IMRT capabilities as other treatment machines in the Radiation Oncology Department.

During the study, the position of the gold markers seen on x-ray will be used to make adjustments to the position of your prostate for your radiation therapy treatment. The positions reported by the fiducial system will be recorded and used for daily treatment.

Three (3) times per week, you will have a CT scan of your prostate. The CT scans will be performed just before the delivery of radiation. Radiotherapists will assist you onto the treatment table and position it for your treatment. The treatment table will then be rotated 180 degrees from the treatment machine and the CT scan of your prostate will be performed. After the CT scan, which will take about 5-8 minutes, the couch will be rotated back to the original position.

A trans-abdominal ultrasound of your prostate will also be performed twice per week for the first two weeks and then once a week from then on while you are on study. The M. D. Anderson staff and researchers will analyze the changes in prostate movement during radiation therapy using the scanned CT images and ultrasound images and compare them with positional changes displayed by the fiducial-based system.

Targeting of your prostate on a daily basis will be performed using the fiducial-based system. This will involve performing a pair of x-rays before your treatment. A shift will be made if needed using the implanted prostate markers. The position of the seeds after the shift will be routinely verified with another pair of x-rays. After alignment has occurred, a radiation treatment will then be delivered.

This is an investigational study. The fiducial-based system is FDA-approved. A total of 20 patients will take part in this study. All will be enrolled at M. D. Anderson.

Study participants with prostate cancer that will be treated with external beam radiation therapy.

Inclusion Criteria:

1. Patients with pathologic diagnosis of prostate cancer
2. Patients must plan to have external beam radiation as the definitive treatment for their prostate cancer with daily localization.
3. Patients must be able to tolerate transrectal or transperineal implantation of three fiducial markers into the prostate.
4. Patients must be able to tolerate frequent (e.g. three CT scans per week) CT scanning.
5. Patients must be able to lie flat and still for the duration of the fiducial-based localization and CT scanning sessions.
6. Patients must have anatomy that will allow an adequate pelvic image on portal imaging and CT scanning.
7. If patients received hormone therapy, then it must have started more than 8 weeks prior to implantation of fiducials.
8. Patients on hormonal therapy at the time of simulation must remain on hormone therapy until their radiation course is complete.
9. Patients must understand and sign informed consent.

Exclusion Criteria:

1. Patients who are not candidates for trans-rectal prostate biopsy or cannot tolerate placement of three fiducial prostate markers.
2. Patients with an estimated prostate volume of less than 20 cc.
3. Patients who have had prior prostate surgery or are planned to have prostate surgery for prostate cancer.
4. Patients who have had previous radiation therapy to the pelvis.
5. Patients who have had prior prostate brachytherapy implant or who have a planned course of therapy using prostate brachytherapy (permanent seeds or high dose rate).
6. Patients with a body habitus that the CT bore of the CT/Linac treatment machine cannot accommodate (i.e. height greater than 6' 3" or body weight greater than 300 pounds).
7. Patients on anticoagulant medication (e.g., coumadin, clopidogrel, low-molecular weight heparin) other than aspirin will not be eligible. Patients on aspirin should discontinue aspirin 7 days prior to fiducial placement and for 5 days afterward.
8. Patients with hip prostheses will not be eligible.